Prostate cancer prevention: what do we know now and when will we know more?
Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.
Thompson
Ian M
IM
Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. thompsoni@uthscsa.edu
Basler
Joseph
J
Hensley
Deborah
D
von Merveldt
Dendra
D
Jenkins
Carol A
CA
Higgins
Betsy
B
Leach
Robin
R
Troyer
Dean
D
Pollock
Brad
B
D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012643:Selenium / Q000008:administration & dosage / Q000627:therapeutic use*; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
D000975:Antioxidants; D014408:Biomarkers, Tumor; D014810:Vitamin E; D012643:Selenium